{bio,medical} informatics
bookmark:
connotea
::
del.icio.us
::digg
::furl
::reddit
::yahoo::
The Motley Fool
New Tune at Celera: Should it stay or should it go now?
[requires 'free' registration]
"Possible reasons for Venter's departure range from the company's transition from bioinformatics to drug discovery and development, to personality conflicts between Venter and White, to Venter's preference for research to running a business. But the bottom line is clear: Whatever role Venter will play, his visionary leadership will no longer be at the top. Does that mean an end to Celera's business momentum, or does realizing value for shareholders require replacing the founding science brainiacs with MBAs?
We asked Motley Fool community members on the Celera, Biotechnology, Rule Breaker Strategies, and Rule Breaker Companies discussion boards to share their views about Venter's departure and Celera's business, especially in light of the Rule Breaker criteria."
redux [10.31.01]
"To employ the method described in this article, it is important to ensure that all the firms being compared are similar in their developmental architecture. Typically, investors would use a set of comparable firms in valuing a firm but for illustration purposes, consider only one example. Exilixis - a company pioneering the use of genetically manipulatable model systems for biomedical research - should be compared to a company like Millenium, which has a highly integral development architecture, using a variety of technologies to develop biopharmaceuticals. The analysis shows that Exilixis is undervalued relative to Millennium.
A quick glance at equity reports shows Celera Genomics is compared to a variety of companies including Millennium. A company such as Celera, at this point in its development, has more in common with a "modular" company such as Incyte - and analysis shows it is overvalued in relation to Incyte. Of course, to be fair to Celera, it is attempting to forward integrate into a structure similar to Millennium. The market suggests that it is midway in the continuum between modular and integral development structures."
[ rhetoric ]
“Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.”
BIOINFORMATICS IN THE 21st CENTURY[ search ]
[ outbound ]
biospace
/
genomeweb
/
bio-it world
/
scitechdaily
/
biomedcentral
/
the panda's thumb
/
bioinformatics.org
/
nodalpoint
/
flags and lollipops
/
on genetics
/
a bioinformatics blog
/
andrew dalke
/
the struggling grad student
/
in the pipeline
/
gene expression
/
free association
/
pharyngula
/
the personal genome
/
genetics and public health blog
/
the medical informatics weblog
/
linuxmednews
/
nanodot
/
complexity digest
/
eyeforpharma
/
nsu
/
nyt science
/
bbc scitech
/
newshub
/
biology news net
/
informatics review
/
stanford
/
bmj info in practice
/
bmj info in practice
/
[ schwag ]
look snazzy and support the site at the same time by buying some snowdeal schwag !
[ et cetera ]
valid xhtml 1.0?
This site designed by
Eric C. Snowdeal III
.
© 2000-2005